Device Trial Radar · NCT06111508
The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Nov 29, 2023
Primary completion
Sep 13, 2024
Study completion Sep 16, 2024
Sponsor
- Lead sponsor
- University of VirginiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novo Nordisk A/S
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare the effect of a continuous glucose monitor (CGM) based titration algorithm to standard titration by self-monitoring blood glucose (SMBG) in participants with Type 2 Diabetes already using long acting insulin. The comparison aims to study the difference in glycemic control between the two therapies. Participants will be followed for 18 weeks and will be provided with Degludec insulin, insulin pen, and a CGM (Dexcom G6).
Conditions
- Type 2 Diabetes
Interventions
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAsDevice
A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Time in Range 3.9-10.0 mmol/L (70-180 mg/dL)Time frame: From baseline (-2 to 0 weeks) to weeks 14-16 (2 weeks)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Icahn School of Medicine at Mount Sinai
New York, New York
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.